SCHEMBL6350535

SCHEMBL6350535

CN1CCN(Cc2ccc3c(c2)C=C/C(=C2/C(=O)Nc4ccccc42)N3)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCB P05771 1/20 0.42
PRKCA P17252 1/20 0.42
PRKCH P24723 1/20 0.42
PRKCE Q02156 1/20 0.42
PRKCQ Q04759 1/20 0.42
PRKCD Q05655 1/20 0.42
CHKA P35790 2/20 0.40
MC4R P32245 1/20 0.40
IDO1 P14902 1/20 0.40
TDO2 P48775 1/20 0.40
IDO2 Q6ZQW0 1/20 0.40
ACHE P22303 1/20 0.39
HTR1A P08908 1/20 0.39
DRD2 P14416 1/20 0.39
HTR2A P28223 1/20 0.39
HTR6 P50406 1/20 0.39
KDR P35968 4/20 0.39
PDGFRB P09619 1/20 0.39
FGFR1 P11362 1/20 0.39
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6350539 1.00 PRKCB (0.42) PRKCBPRKCAPRKCHPRKCEPRKCQ
SCHEMBL6353001 0.92 ALDH1A1 (0.38) PRKCBPRKCAPRKCHPRKCEPRKCQ
SCHEMBL6353004 0.92 ALDH1A1 (0.38) PRKCBPRKCAPRKCHPRKCEPRKCQ
SCHEMBL6353239 0.84 MEN1 (0.43) DRD2MEN1KMT2AALDH1A1KDM4E
SCHEMBL6353236 0.84 MEN1 (0.43) DRD2MEN1KMT2AALDH1A1KDM4E
SCHEMBL6355402 0.79 NTRK1 (0.38) IDO1TDO2KDRALDH1A1LMNA
SCHEMBL6355403 0.79 NTRK1 (0.38) IDO1TDO2KDRALDH1A1LMNA
SCHEMBL6348639 0.79 CDK5 (0.47) KDRMEN1KMT2AALDH1A1
SCHEMBL6348635 0.79 CDK5 (0.47) KDRMEN1KMT2AALDH1A1
SCHEMBL6434497 0.77 TNKS2 (0.44) HTR1ADRD2HTR6KDRPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050090498-A1 3-Quinolin-2(1h)-ylideneindolin-2-one derivative YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 2005-04-28 US disclosed
EP-1396490-A1 3-QUINOLINE-2-(1H)-YLIDENEINDOLIN-2-ONE DERIVATIVES YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2004-03-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050090498-A1 3-Quinolin-2(1h)-ylideneindolin-2-one derivative KDR, FLT4, FLT1 PRKCB 2644/4885PRKCA 2274/4885PRKCH 2638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.